Japanese Doctors Report Success Using Bone Drug to Treat Mesothelioma, According to Surviving Mesothelioma

Share Article

Scientists in Japan say they have new evidence that a drug normally used to treat osteoporosis and cancer-related bone loss may also help in the fight against malignant mesothelioma.

Bone Drug for Mesothelioma

Novel Mesothelioma Treatment?

Zoledronic acid produced synergistic cytotoxic effects with cisplatin, the first-line chemotherapeutic agent for mesothelioma.

Researchers at several Japanese universities have demonstrated the potential of a bisphosphonate drug called zoledronic acid as a novel mesothelioma therapy. Surviving Mesothelioma has just posted an article on their findings. Click here to read it how.

The research led by scientists at Chiba University found that when zoledronic acid was administered into the pleural cavities of mice infected with mesothelioma, mesothelioma tumor growth was suppressed.

“We also showed that zoledronic acid produced synergistic cytotoxic effects with cisplatin, the first-line chemotherapeutic agent for mesothelioma,” writes Chiba University’s Yuji Tada, the first author on the paper.

The new study published online by Springer Plus details the team’s plan to conduct a Phase I study of zoledronic acid’s safety and effectiveness in previously treated human mesothelioma patients. Eventually, they plan to test it in combination with mesothelioma chemotherapy.

“This especially encouraging for the mesothelioma community because it makes use of a drug that already exists and is FDA approved,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “If zoledronic acid does turn out to be a viable mesothelioma treatment, it could be used in clinical practice relatively quickly.”

To find out more about zoledronic acid and the Japanese research findings, see Osteoporosis Drug Shows Promise as Novel Mesothelioma Treatment, now available on the Surviving Mesothelioma website.

Tada, Y, et al, “An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol”, February 27, 2016, Springer Plus, http://link.springer.com/article/10.1186%2Fs40064-016-1893-2

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website